GMMMG logo

NHS photos

NHS logo

News

<< Back

News Summary

From this page you will be able to access a summary of additions or changes to the GMMMG website during February 2018

February 2018 

Formulary and Managed Entry Subgroup (FMESG)

22.2.18

The following actions [Link removed - consultation closed] were proposed at the Jan 2018 FMESG meeting, approved in principle by GMMMG in February, and are now open for GM wide consultation. Comments are invited up until 5pm Tuesday 20th March 2018 and should be submitted here [Link removed - consultation closed].

Pathways and Guidelines Development Subgroup (PaGDSG)

21.2.18

The following reviewed and updated Shared Care Protocols were approved at the February 2018 meeting of the GMMMG:

  • Azathioprine in Dermatology
  • Hydroxychloroquine in Dermatology
  • Mycophenolate mofetil in Dermatology
  • Ciclosporin in Dermatology

21.2.18

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Protocol for  Oral methotrexate in Dermatology [Link removed - consultation closed] is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm on 20th March 2018. Comments should be submitted here [Link removed - consultation closed] after which it will be reviewed, amended as required and then taken to GMMMG for final approval.

The Pharmaceutical Industry is invited to comment on factual inaccuracies only.

21.2.18

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Protocol for  Azathioprine in Neurological Conditions [Link removed - consultation closed] is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm on 20th March 2018. Comments should be submitted here [Link removed - consultation closed] after which it will be reviewed, amended as required and then taken to GMMMG for final approval.

The Pharmaceutical Industry is invited to comment on factual inaccuracies only.

GMMMG

23.2.18

GMMMG CSB has recently approved the Greater Manchester Trans-Anal Irrigation (TAI) Pathway. (See Clinical Guidance and pathways). There were no commissioning or funding implications associated with this pathway, as it consolidates current practice. This pathway aims to reduce variation in treatment across GM, by ensuring that GPs are following the same follow the same pathway for trans-anal irrigation systems. It also aims to remove unnecessary delay in treatment and support regular review of the patient by the specialist.

20.2.18

GM antimicrobial (although not the dental section) has undergone its quarterly review and is available on the guidance page of the GMMMG website

20.2.18

GMMMG has temporarily suspended its recommendation on Ulipristal (Esmya®) for uterine fibroids pending the outcome of the MHRA saefty review

9.2.18

GMMMG met on Thursday the 8th of February 2018. The outputs are to be ratified by AGG prior to publication on the website. However, the subgroup minutes and updated work plans are now available

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer